Does dopamine contribute to striatal damage caused by impaired mitochondrial function?

Annals of the New York Academy of Sciences

Volumn 893, Issue , 1999, Pages 345-349

  Maragos, William F ^a   Jakel, Rebekah J ^a   Chesnut, M Dathan ^a   Geddes, James W ^a   Dwoskin, Linda P ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; DOPAMINE; MALONIC ACID;

ANIMAL EXPERIMENT; BRAIN MITOCHONDRION; BRAIN SYNAPTOSOME; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; DOPAMINE UPTAKE; NONHUMAN; RAT;

ANIMALIA;

EID: 0033373010     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07851.x     Document Type: Conference Paper

References (14)

1. 1. Martin, J.B. & J.F. Gusella. 1986. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315: 1267-1276.
2. 2. Beal, M.F. et al. 1993. Neurochemical and histological characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13: 4181-4192.
3. 3. Greene, J.G. et al. 1993. Inhibition of succinate dehydrogenase by malonic acid produces an excitotoxic lesion in rat striatum. J. Neurochem. 61: 1151-1154.
4. 3H]dopamine uptake in the nucleus accumbens, striatum and frontal cortex of rats. J. Pharmacol. Exp. Ther. 270: 133-141.
5. 5. Maragos, W.F. et al. 1998. 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. Exp. Neurol. 154: 637-644.
6. 6. Maragos, W.F. et al. 1999. Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res. 834: 168-172.
7. 7. McLaughlin, B.A. et al. 1998. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. J. Neurochem. 70: 2406-2415.
8. 8. Reynolds, D.S. et al. 1998. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 18: 10116-10127.
9. 9. Chapman, A.G. et al. 1989. Excitotoxicity of NMDA and kainic acid is modulated by nigrostriatal dopaminergic fibers. Neurosci. Lett. 107: 256-260.
10. 10. Buisson, A. et al. 1991. Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid. Neurosci. Lett.131: 257-259.
11. 11. Rosenberg, P.A. 1988. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J. Neurosci. 8: 2887-2894.
12. 12. Hastings, T.G. et al. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93: 1956-1961.
13. 13. Spina, M.B. & G. Cohen. 1989. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc. Natl. Acad. Sci. USA 86: 1398-1400.
14. 14. Smith, T.S. et al. 1994. L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? NeuroReport 5: 1009-1011.